This preview shows pages 1–2. Sign up to view the full content.
This preview has intentionally blurred sections. Sign up to view the full version.View Full Document
Unformatted text preview: The consulting firm Merck hired to recommend the price of the vaccine suggested a price of $120 per dose. Gardasil is the first vaccine to prevent a type of cancer. Merck invested over a billion dollars in developing Gardasil. They price per dose not only needed to be set to cover these costs, but also to help the company raise its stock price. Industry analysts projected annual revenues of $4 billion. 4. Cervarix, another HPV vaccine, was being developed by GlaxoSmithKline. Cevarix had a similar safety profile and efficacy as Gardasil. Cevarix protected only against HPV types 16 and 18. Cevarix was a year behind Gardasil in terms of FDA approval and its launch. Questions 1. What do you think the public’s reaction would be to Gardasil not eliminating the need for annual Pap exams in women? 2. At what price would you set Gardasil?...
View Full Document
This note was uploaded on 10/16/2010 for the course B&E BADM 691 taught by Professor France during the Spring '10 term at WVU.
- Spring '10